With an ever increasing burden of diabetes mellitus in India, aggressive but safe and effective pharmacotherapy is very important. Dipeptidyl peptidase 4 (DPP-4) inhibitors have emerged as a promising option for doctors to manage type 2 diabetes mellitus. Are all molecules of this class equally safe and effective? What should be the considerations while prescribing these?
Prevalence of Diabetes According to International Diabetes Federation (IDF), 415 million people have been diagnosed with diabetes mellitus around the world. The data by IDF also suggests that there will be a spike in the number of diabetic patients in next two decades and by the year 2040 the estimated number may rise to 642 million. IDF figures also show that India is one of the largest contributors in the world diabetic population with almost 7.5 crore cases of diabetes till the year 2015. However, this is just an…
